Precigen Inc Stock Price, News & Analysis

Precigen, Inc. (Nasdaq: PGEN) has successfully closed its underwritten public offering of 42,857,143 shares of common stock at a price of $1.75 per share. The offering generated gross proceeds of approximately $75.0 million before expenses. J.P. Morgan Securities LLC and Cantor Fitzgerald & Co. were the lead managers. The offering was made under an effective shelf registration statement filed with the SEC. Precigen focuses on advancing gene and cell therapies targeting various diseases, including cancer and autoimmune disorders, emphasizing the development of affordable biotherapeutics.

Precigen, Inc. (PGEN) has announced the pricing of a public offering of 42,857,143 shares of its common stock at $1.75 per share, targeting gross proceeds of approximately $75.0 million. The underwriters have a 30-day option to purchase an additional 6,428,571 shares. The offering is expected to close on January 27, 2023, subject to customary conditions. Proceeds will fund the development of clinical and preclinical candidates and general corporate purposes. The offering is made under a shelf registration statement effective since July 2, 2020.

Precigen, Inc. (Nasdaq: PGEN) has announced a public offering of $75 million of its common stock, with an additional $11.25 million available through underwriters' options. This offering, subject to market conditions, involves all shares being sold by the company. J.P. Morgan Securities LLC is the lead manager for this offering, with support from Cantor Fitzgerald & Co. and others. The offering is made under a shelf registration statement that became effective on July 2, 2020. Precigen's mission involves advancing gene and cell therapies for urgent diseases. The company emphasizes that the completion of the offering is uncertain.

Precigen (NASDAQ: PGEN) reported positive Phase 1 clinical trial results for its investigational PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis (RRP). Key findings include:

• 50% of patients achieved Complete Response, requiring no surgeries within 12 months post-treatment.
• Median surgeries decreased from 6.5 to 0.5 for treated patients.
• 32 patients are currently enrolled in Phase 2, with future regulatory discussions pending.

These results suggest a significant reduction in surgical intervention and a potential shift in treatment paradigms for RRP.

Precigen (PGEN) presented significant clinical progress at the 41st Annual J.P. Morgan Healthcare Conference. The company highlighted advancements in its UltraCAR-T and AdenoVerse programs throughout 2022. Key updates include ongoing Phase 2 trials for PRGN-2012, aimed at treating recurrent respiratory papillomatosis, and positive Phase 1 data for PRGN-3006 in acute myeloid leukemia. Precigen plans to host an R&D Day on January 24, 2023, to discuss safety and efficacy data from its ongoing studies.

Precigen, a biopharmaceutical company, is set to host an investigator-led R&D event on January 24, 2023, at 4:30 PM ET. The focus will be on the first-in-class PRGN-2012 AdenoVerse Immunotherapy targeting recurrent respiratory papillomatosis (RRP). The event will present complete Phase 1 clinical trial safety and efficacy data, featuring insights from key officials including Clint T. Allen, MD, and Helen Sabzevari, PhD. The company aims to demonstrate the potential of PRGN-2012 for the underserved RRP patient population.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company focusing on gene and cell therapies, announced that its CEO, Helen Sabzevari, PhD, will present a corporate and clinical overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:45 PM PT in San Francisco, California. Participants can register to view the event on Precigen's website under the Events & Presentations section. Precigen is advancing therapies in immuno-oncology and other critical areas, working towards innovative solutions in biotherapeutics.

Precigen announced positive Phase 1 data for PRGN-3006 UltraCAR-T at the ASH Annual Meeting. The treatment showed a 27% objective response rate (ORR) in heavily pre-treated relapsed/refractory acute myeloid leukemia (AML) patients following lymphodepletion. Notably, 60% of patients experienced a decrease in bone marrow blasts. The therapy was well-tolerated with no dose-limiting toxicities reported, highlighting its safety profile. PRGN-3006 has received both Orphan Drug and Fast Track Designations from the FDA, underscoring its potential in addressing critical cancer treatment gaps.

Precigen, Inc. (Nasdaq: PGEN) reported a significant revenue increase of over 200% to $13.4 million for Q3 2022, driven by collaboration and licensing agreements. The company has retired $144 million of convertible notes, saving $5.4 million in interest. Ongoing clinical trials include PRGN-2012 for recurrent respiratory papillomatosis, and data will be showcased in January 2023. Cash reserves were reported at $153.8 million as of September 30, 2022. Precigen remains focused on its gene and cell therapy pipeline, indicating a substantial cash runway into Q4 2023.